Senores Pharmaceuticals (NSE:SENORES) 1-Year Sharpe Ratio: 2.15 (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
19 GF Score
Price ₹1,428.40
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals 1-Year Sharpe Ratio?

Senores Pharmaceuticals NSE:SENORES -0.14% 19 1-Year Sharpe Ratio is 2.15 as of Sep. 07, 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 19/100. The stock has 7 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-07), Senores Pharmaceuticals's 1-Year Sharpe Ratio is 2.15.

Senores Pharmaceuticals  (NSE:SENORES) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Senores Pharmaceuticals 1-Year Sharpe Ratio Related Terms

NSE:SENORES vs LLY, JNJ, ABBV: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senores Pharmaceuticals 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Senores Pharmaceuticals's 1-Year Sharpe Ratio falls into.


NSE:SENORES
19GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 2.15 mean?
Senores Pharmaceuticals (NSE:SENORES) has a 1-Year Sharpe Ratio of 2.15 as of Sep. 07, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Senores Pharmaceuticals and its competitors.
Is Senores Pharmaceuticals' 1-Year Sharpe Ratio too high?
Senores Pharmaceuticals' current 1-Year Sharpe Ratio is 2.15. Overall, Senores Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' 1-Year Sharpe Ratio compare to LLY and JNJ?
Senores Pharmaceuticals' 1-Year Sharpe Ratio of 2.15 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Senores Pharmaceuticals and its competitors. Senores Pharmaceuticals's current 1-Year Sharpe Ratio is 2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current 1-Year Sharpe Ratio of 2.15. The current 1-Year Sharpe Ratio is 2.15. Senores Pharmaceuticals' overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current 1-Year Sharpe Ratio is 2.15 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
19GF Score

Get the complete analysis for NSE:SENORES

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,428.40
Price